Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P15289: Variant p.Cys300Phe

Arylsulfatase A
Gene: ARSA
Feedback?
Variant information Variant position: help 300 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Cysteine (C) to Phenylalanine (F) at position 300 (C300F, p.Cys300Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In MLD; late-infantile-onset; enzyme activity reduced to less than 1%; the mutant protein is more rapidly degraded in lysosomes; strongly interferes with the octamerization process of the enzyme at low pH. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 300 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 507 The length of the canonical sequence.
Location on the sequence: help ADNGPETMRMSRGGCSGLLR C GKGTTYEGGVREPALAFWPG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 19 – 507 Arylsulfatase A
Chain 19 – 444 Arylsulfatase A component B
Binding site 281 – 281
Binding site 282 – 282
Binding site 302 – 302
Disulfide bond 300 – 414



Literature citations
Metachromatic leucodystrophy in Portugal-finding of four new molecular lesions: C300F, P425T, g.1190-1191insC, and g.2408delC.
Marcao A.; Amaral O.; Pinto E.; Pinto R.; Sa Miranda M.C.;
Hum. Mutat. 13:337-338(1999)
Cited for: VARIANTS MLD PHE-300 AND THR-425; Biochemical characterization of two (C300F, P425T) arylsulfatase A missense mutations.
Marcao A.; Simonis H.; Schestag F.; Sa Miranda M.C.; Gieselmann V.;
Am. J. Med. Genet. A 116:238-242(2003)
Cited for: CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425; Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T.
Marcao A.; Azevedo J.E.; Gieselmann V.; Sa Miranda M.C.;
Biochem. Biophys. Res. Commun. 306:293-297(2003)
Cited for: CHARACTERIZATION OF VARIANTS MLD PHE-300 AND THR-425;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.